Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel

LDL-Rezeptor-related-Protein 5

Das LRP5-Gen kodiert einen LDL-Rezeptor, der das gebundene LDL mittels Endozytose internalisiert. Dieser Rezeptor spielt eine wichtige Rolle im Knochen- und Leberstoffwechselsowie im Auge. Mutationen sind für verschiedene Störungen des Knochen-Mineralhaushaltes verantwortlich. Im Auge wird die exudative Vitreoretinopathie Typ 4 ausgelöst und in der Leber können sich multiple Zysten bilden.

Gentests:

Klinisch Untersuchungsmethoden Familienuntersuchung
Bearbeitungszeit 5 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Hochdurchsatz-Sequenzierung
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Forschung Untersuchungsmethoden Direkte Sequenzierung der proteinkodierenden Bereiche eines Gens
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Forschung Untersuchungsmethoden Multiplex ligationsabhängige Amplifikation
Bearbeitungszeit 25 Tage
Probentyp genomische DNS

Verknüpfte Erkrankungen:

Autosomal dominante Osteopetrose 1
LRP5
Polyzystische Lebererkrankung
LRP5
Polyzystische Lebererkrankung 1
PRKCSH
Polyzystische Lebererkrankung 2
SEC63
Osteoporose
CASR
LRP5
RXRA
VDR

Referenzen:

1.

Magoori K et al. (2003) Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E.

[^]
2.

Van Wesenbeeck L et al. (2003) Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.

[^]
3.

None (1995) Familial exudative vitreoretinopathy.

[^]
4.

Shastry BS et al. (1997) Familial exudative vitreoretinopathy: further evidence for genetic heterogeneity.

[^]
5.

Hey PJ et al. (1998) Cloning of a novel member of the low-density lipoprotein receptor family.

[^]
6.

Dong Y et al. (1998) Molecular cloning and characterization of LR3, a novel LDL receptor family protein with mitogenic activity.

[^]
7.

de Crecchio G et al. (1998) Autosomal recessive familial exudative vitreoretinopathy: evidence for genetic heterogeneity.

[^]
8.

Chen D et al. (1999) Molecular cloning of mouse Lrp7(Lr3) cDNA and chromosomal mapping of orthologous genes in mouse and human.

[^]
9.

Mao J et al. (2001) Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway.

[^]
10.

Twells RC et al. (2001) The sequence and gene characterization of a 400-kb candidate region for IDDM4 on chromosome 11q13.

[^]
11.

Gong Y et al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

[^]
12.

Little RD et al. (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

[^]
13.

Kato M et al. (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor.

[^]
14.

Boyden LM et al. (2002) High bone density due to a mutation in LDL-receptor-related protein 5.

[^]
15.

Fujino T et al. (2003) Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion.

[^]
16.

Twells RC et al. (2003) Haplotype structure, LD blocks, and uneven recombination within the LRP5 gene.

[^]
17.

Kondo H et al. (2003) Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity.

[^]
18.

Mizuguchi T et al. (2004) LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density.

[^]
19.

Toomes C et al. (2004) Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q.

[^]
20.

Ferrari SL et al. (2004) Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites.

[^]
21.

Jiao X et al. (2004) Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5.

[^]
22.

Semënov M et al. (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.

[^]
23.

Qin M et al. (2005) Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes.

[^]
24.

Ai M et al. (2005) Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.

[^]
25.

Clément-Lacroix P et al. (2005) Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice.

[^]
26.

Guo YF et al. (2006) Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study.

[^]
27.

Qin M et al. (2008) Moderate reduction of Norrin signaling activity associated with the causative missense mutations identified in patients with familial exudative vitreoretinopathy.

[^]
28.

Yadav VK et al. (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum.

[^]
29.

Narumi S et al. (2010) Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome: identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray.

[^]
30.

Cui Y et al. (2011) Lrp5 functions in bone to regulate bone mass.

[^]
31.

Orphanet article

Orphanet ID 123115 [^]
32.

NCBI article

NCBI 4041 [^]
33.

OMIM.ORG article

Omim 603506 [^]
Update: 29. April 2019